Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

Most Observers Still Want More Detailed Data From Urothelial Cancer Study

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.

Seagen/Astellas announced topline results from the Phase Ib/II study of Padcev/Keytruda in urothelial cancer • Source: Shutterstock

Topline results from Seagen Inc. /Astellas Pharma, Inc.’s Phase Ib/II EV-103 trial of Padcev (enfortumab vedotin-ejfv) and Merck & Co., Inc.’s Keytruda (pembrolizumab) in first-line unresectable locally advanced or metastatic urothelial cancer may help bolster investor enthusiasm around the alleged efforts by Merck to buy Seagen. The results themselves look incrementally positive, but it is likely more data will need to come out to provide a sense of how the results might affect practice.

Seagen and Astellas said on 26 July that results demonstrated a 64.5% objective response rate (ORR) in the EV-103 trial...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.